JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M204499200 on September 9, 2002

J. Biol. Chem., Vol. 277, Issue 47, 45393-45399, November 22, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/47/45393    most recent
M204499200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, F.
Right arrow Articles by Greengard, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, F.
Right arrow Articles by Greengard, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Mechanism of Regulation of Casein Kinase I Activity by Group I Metabotropic Glutamate Receptors*

Feng LiuDagger , David M. Virshup§, Angus C. NairnDagger ||, and Paul GreengardDagger

From the Dagger  Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10021, the § Division of Hematology/Oncology, Department of Pediatrics, Program in Human Molecular Biology and Genetics, University of Utah, Salt Lake City, Utah 84112, and the  Department of Psychiatry, Yale University, New Haven, Connecticut 06520

Received for publication, May 8, 2002, and in revised form, August 6, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Previously, we reported that (S)-3,5-dihydroxypenylglycine (DHPG), an agonist for group I metabotropic glutamate receptors (mGluRs), stimulates CK1 and Cdk5 kinase activities in neostriatal neurons, leading to enhanced phosphorylation, respectively, of Ser-137 and Thr-75 of DARPP-32 (dopamine and cAMP-regulated phosphoprotein, 32 kDa). We have now investigated the signaling pathway that leads from mGluRs to casein kinase 1 (CK1) activation. In mouse neostriatal slices, the effect of DHPG on phosphorylation of Ser-137 or Thr-75 of DARPP-32 was blocked by the phospholipase Cbeta inhibitor U73122, the Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA/AM), and the calcineurin inhibitor cyclosporin A. In neuroblastoma N2a cells, the effect of DHPG on the activity of transfected HA-tagged CK1epsilon was blocked by BAPTA/AM and cyclosporin A. In neostriatal slices, the effect of DHPG on Cdk5 activity was also abolished by BAPTA/AM and cyclosporin A, presumably through blocking activation of CK1. Metabolic labeling studies and phosphopeptide mapping revealed that a set of C-terminal sites in HA-CK1epsilon were transiently dephosphorylated in N2a cells upon treatment with DHPG, and this was blocked by cyclosporin A. A mutant CK1epsilon with a nonphosphorylatable C-terminal domain was not activated by DHPG. Together, these studies suggest that DHPG activates CK1epsilon via Ca2+-dependent stimulation of calcineurin and subsequent dephosphorylation of inhibitory C-terminal autophosphorylation sites.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Casein kinase 1 (CK1)1 was one of the first serine/threonine protein kinases to be isolated and characterized. There are at least seven mammalian CK1 isoforms (alpha , beta , gamma 1, gamma 2, gamma 3, delta , and epsilon  (1, 2)), and distinct CK1 family members are likely to have a variety of roles in eukaryotic cells. An increasing number of potential physiologic substrates for CK1 isoforms have been identified. CK1alpha phosphorylates M1 and M3 muscarinic receptors and rhodopsin in an agonist-dependent manner (3, 4). CK1epsilon and CK1delta phosphorylate N-terminal residues of p53 in vitro and in vivo, and DNA-damaging drugs enhance this activity (4-6). CKIepsilon is an important regulator of beta -catenin in the Wnt pathway; CKIepsilon mimicked Wnt in inducing a secondary axis in Xenopus, stabilizing beta -catenin, and stimulating beta -catenin-dependent gene transcription (7-11). In Drosophila, the double-time gene product, a CK1epsilon homolog, has been found to interact with dPER and regulate circadian cycle length (12). CK1delta and CK1epsilon have also both been implicated in the regulation of the circadian clock in mammals (13-15).

CK1 family members contain a highly related, central kinase domain that is flanked by N- and C-terminal extensions of variable length. The amino acid sequences of the C-terminal extensions are in general not highly related. However, the 124-amino acid C-terminal domain of mammalian CK1epsilon is 50% identical to that of CK1delta . Notably, several in vitro studies have shown that the activities of CK1delta and CK1epsilon are regulated by autophosphorylation of their respective C-terminal domains (16, 17). Autophosphorylation of more than eight sites leads to inhibition of kinase activity. Moreover, it has been shown in vitro that treatment of CK1epsilon with several different serine/threonine phosphatases including PP1, PP2A, and PP2B (calcineurin) causes a marked increase in kinase activity (13, 17, 18). Dephosphorylation of CK1delta and CK1gamma isoforms by the catalytic subunit of PP1 has also been found in vitro to result in enzyme activation (16).

Recently, we have reported that both CK1 and Cdk5 are regulated by activation of metabotropic glutamate receptors (mGluRs) in neostriatal neurons (19). DHPG, an agonist for group I mGluRs, increased CK1 and Cdk5 activities in neostriatal slices, leading to enhanced phosphorylation of Ser-137 and Thr-75 of DARPP-32, respectively. The effects of DHPG on both Ser-137 and Thr-75 were blocked by CK1-7 and IC261, specific inhibitors of CK1, suggesting that activation of Cdk5 by mGluRs required activation of CK1. In support of this possibility, the DHPG-induced increase in Cdk5 activity, subsequently measured in extracts of neostriatal slices, was abolished by treatment of slices with CK1-7 or IC261. Finally, treatment of acutely dissociated neurons with DHPG enhanced voltage-dependent Ca2+ currents. This enhancement was eliminated by either CK1-7 or butyrolactone (an inhibitor of Cdk5), indicating that CK1 and Cdk5 may be involved in the regulation by mGluR agonists of Ca2+ channels.

In the present study, we have investigated the processes that lead from mGluRs to CK1 activation and the mechanism that underlies CK1 activation in response to group I mGluR agonists. The results obtained support a signal transduction pathway in which group I mGluRs increase intracellular Ca2+ and stimulate calcineurin to dephosphorylate autoinhibitory phosphorylation sites in CK1epsilon . Transient dephosphorylation and subsequent autophosphorylation of CK1epsilon leads to transient activation and inactivation, respectively, of the enzyme.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Antibodies, Plasmids, and Chemicals-- Phosphospecific antibodies that recognize either phospho-Ser-137 DARPP-32 or phospho-Thr-75 DARPP-32 were developed as described (19, 20). The expression plasmids pCDP4HA-CKIepsilon and pCS-Myc-MM2-CK1epsilon were prepared as described (18). Anti-HA (12CA5) was obtained from Roche Molecular Biochemicals and anti-Myc (9E10) from Upstate Biotechnology. Anti-Cdk5 (C-8) and anti-CKIepsilon were obtained from Santa Cruz Biotechnology. U73122, BAPTA/AM, and cyclosporin A were obtained from Calbiochem; (S)-3,5-DHPG, ZM241385, and L-AP3 were obtained from Tocris. Protease inhibitor mixture tablets were obtained from Roche Molecular Biochemicals. Lambda protein phosphatase was obtained from Upstate Biotechnology.

Preparation and Treatment of Striatal Slices-- Neostriatal slices were prepared from male C57/BL6 mice (6-8 weeks old) as described (21). Briefly, coronal (usually 3-4/mouse) slices (350 µm) were prepared using a vibratome. From each coronal slice, two neostriatal slices (left and right) were dissected. When slices were treated with drugs, one slice from a pair served as a control for the drug-treated slice. After drug treatment, slices were immediately frozen in liquid nitrogen and stored at -80 °C until assayed.

Immunoblotting-- Frozen slices were sonicated in hot homogenization buffer containing 1% SDS and 50 mM NaF, and samples were boiled for 10 min. SDS-PAGE sample buffer was then added, and samples were boiled for 5 min. Samples (~120 µg protein) were separated by SDS-PAGE (10% polyacrylamide) and transferred to nitrocellulose. Immunoblots were first probed with anti-phospho-Ser-137 DARPP-32 antibody. The blots were stripped and probed with anti-phospho-Thr-75 DARPP-32 antibody. Blots were stripped again and probed with anti-total DARPP-32 antibody. Antibody binding was detected by enhance chemiluminescence (ECL) using x-ray film, and images were analyzed by laser scanning densitometry using NIH Image 1.52 software. Data were statistically analyzed by Student's t test in Microsoft Excel software as indicated. For each neostriatal slice sample, the level of phospho-Ser-137 or phospho-Thr-75 was normalized to the total level of DARPP-32. In every individual experiment (i.e. for each mouse brain), a control without drug and a control with DHPG were always included. Results from slices from a single mouse brain were normalized to the control slice without drug (arbitrarily set as 1). The figures show ECL blots that were obtained in some cases from different mouse brains and from different experiments. The cumulative data shown in the bar graphs were obtained from at least three independent experiments.

Transfection, Immunoprecipitation, and Assay of CK1 and Cdk5-- Neuroblastoma N2a cells were cultured to 50-60% confluence in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum. Four µg of the expression plasmid for HA-CK1epsilon or Myc-MM2-CK1epsilon was transfected into N2a cells in 100-mm dishes using FuGENETM 6. Twenty-four hours after transfection, cells were incubated at room temperature in phosphate-buffered Krebs-Henseleit solution (Sigma) for 10 min and then with or without inhibitors for 30 min before treatment with (S)-3,5-DHPG for 2 min. Cells were then lysed in 1 ml of radioimmune precipitation buffer containing 1% Nonidet P-40, 150 mM NaCl, 0.1% SDS, 50 mM Tris, pH 8.0, 5 mM Na3VO4, 20 mM NaF, 20 mM beta -glycerol-phosphate, and protease inhibitors. Lysates were centrifuged at 10,000 × g, and supernatants were used for immunoprecipitation and kinase assay.

For immunoprecipitation of CK1epsilon from N2a cells, lysates (1 mg of total protein) were precleared with 5 µl of mouse IgG (ICN) and 50 µl of protein A-agarose for 30 min. Five µl (~2 µg) of anti-HA antibody was added, and samples were incubated for 1 h at 4 °C. Five µl of anti-mouse rabbit IgG and 50 µl of protein A-agarose were then added for 45 min. Immunocomplexes were washed three times in lysis buffer and two times in kinase buffer (30 mM Hepes, pH 7.5, 7 mM MgCl2, 0.5 mM dithiothreitol).

CK1 assays were performed in a 30-µl assay volume with 2 µg of purified DARPP-32, 500 µM ATP, and 5 µCi of [gamma -32P]ATP. Samples were incubated at 30 °C for 10 min, and reactions were stopped by the addition of SDS sample buffer and boiled for 5 min. Samples were separated by SDS-PAGE (12% polyacrylamide). SDS-polyacrylamide gels were dried and exposed to Kodak film for autoradiography. Results were quantified using a PhosphorImager (Amersham Biosciences). The amount of HA-CK1epsilon in each immunoprecipitated sample was determined by immunoblotting using an anti-HA antibody. Kinase activity in each immunoprecipitated sample was normalized to total HA-CK1epsilon . Immunoprecipitation and assay of Cdk5 were performed as described (19).

Immunoprecipitated CKIepsilon , from N2a cells treated with DHPG, was added to a mixture consisting of 50 mM Tris-HCl, 0.1 mM Na2EDTA, 5 mM dithiothreitol, 2 mM MnCl2, and 200 units of lambda phosphatase (Upstate Biotechnology, no. 14-405). Control reactions without lambda protein phosphatase were also performed. Dephosphorylation reactions were incubated at 37 °C for 15 min. To stop the reactions, beads with CKIepsilon were washed three times with radioimmune precipitation buffer and two times with kinase buffer (30 mM Hepes, pH 7.5, 7 mM MgCl2, 0.5 mM dithiothreitol). Kinase activity was measured as described above.

Metabolic Labeling and Two-dimensional Phosphopeptide Mapping-- Twenty-four hours after transfecting N2a cells with CK1epsilon expression plasmids, cells were incubated in 200 µCi/ml (PerkinElmer Life Sciences) of 32P-inorganic phosphate and phosphate-free, serum-free Dulbecco's modified Eagle's medium for 2 h. Cyclosporin A was added to the transiently transfected cultures at a final concentration at 1 µM during the last 30 min of metabolic labeling. Cells were treated with DHPG for various periods of time as indicated, harvested by lysis in radioimmune precipitation buffer, and clarified by centrifugation at 14,000 × g for 10 min. Soluble extracts containing HA- or Myc-tagged proteins were immunoprecipitated with 12CA5 or 9E10 monoclonal antibody and protein A-agarose. The immunoprecipitates were eluted from the protein A-agarose and separated by SDS-PAGE on 10% gel. Protein was stained briefly with Coomassie Brilliant Blue, the gels were dried, and the labeled protein was visualized by autoradiography. Radioactivity was determined using a PhosphorImager and ImageQuant software (Amersham Biosciences).

Radiolabeled protein bands were excised, rehydrated, destained, and dried in a Speedvac. The gel slices were minced and rehydrated in 75 µg/ml TPCK/trypsin in 50 mM NH4CO3H (1 ml final volume) for 24 h at 37 °C. The supernatant was removed from the gel slices and then lyophilized to dryness. Recovery of tryptic phosphopeptides was determined by Cerenkov counting. The two-dimensional peptide mapping method was used to separate phosphopeptides. Lyophilized tryptic peptides were suspended in 10 µl of electrophoresis buffer (10% acetic acid and 1% pyridine, pH 3.5) and spotted onto thin-layer cellulose plates (20 × 20 cm, Analtech). Electrophoresis was carried out at 400 V for 1.5 h. Following electrophoresis, cellulose plates were dried and then subjected to ascending chromatography in buffer containing 25% l-butanol, 7.5% acetic acid, and 37.5% pyridine. Phosphopeptides were visualized using a PhosphorImager and radioactivity in individual phosphopeptides was measured using ImageQuant software (Amersham Biosciences).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The Effect of DHPG on Ser-137 and Thr-75 phosphorylation of DARPP-32 Is Blocked by U73122, BAPTA, and Cyclosporin A-- Previously we showed that DHPG, an agonist for group I mGluRs, increased CK1 and Cdk5 activities in neostriatal slices, leading to enhanced phosphorylation of Ser-137 and Thr-75 of DARPP-32, respectively. Activation of group I mGluRs results in the stimulation of phosphoinositide hydrolysis (22). Therefore, one possible mechanism for DHPG-dependent activation of CK1 might involve activation of PLCbeta . However, it has also been reported that DHPG can potentiate the response of adenosine A2a receptors to agonist (23, 24), raising the possibility of an involvement of other signal transduction pathways. We tested the effect of the specific PLCbeta inhibitor, U73122, in slices. Preincubation with 12.5 µM U73122 for 20 min did not change the basal phosphorylation of Ser-137 or Thr-75, but the effect of DHPG was abolished (Fig. 1). In contrast, the adenosine A2a receptor antagonist, ZM241385 (10 µM), did not affect the ability of DHPG to stimulate phosphorylation of Ser-137 or Thr-75. These results support a role for a signal transduction pathway involving PLCbeta .


View larger version (46K):
[in this window]
[in a new window]
  		Fig. 1.   The effect of DHPG on Ser-137 and Thr-75 phosphorylation of DARPP-32 is blocked by the PLCbeta inhibitor U73122, the Ca2+ chelator BAPTA/AM, and the calcineurin inhibitor cyclosporin A. The effect of the mGluR group I agonist, DHPG, on phosphorylation of DARPP-32 at Ser-137 (CK1 site) and Thr-75 (Cdk5 site) was examined in mouse neostriatal slices using phosphorylation state-specific antibodies. Slices were treated without or with DHPG (100 µM) or ionomycin (Iono., 2 µM) for 2 min following preincubation with vehicle (U73122, 12.5 µM for 20 min), BAPTA/AM (BAPTA, 20 µM for 20 min), cyclosporin A (Cy A, 5 µM for 60 min), or the adenosine A2a receptor antagonist (ZM241385, 10 µM for 20 min). Slices were homogenized and analyzed by SDS-PAGE and immunoblotting using phospho-Ser-137, phospho-Thr-75, and total DARPP-32 antibodies. Immunoblots are shown in the top panel, and cumulative data (means ± S.E.) obtained from three experiments are shown in graphical format in the lower panels. Data for each sample were normalized to the total level of DARPP-32. Data were then normalized to the value obtained in the absence of any addition (-DHPG, set as 1). *, p < 0.05, Student's t test, compared with untreated slices.

Activation of PLCbeta leads to production of inositol 1,4,5-triphosphate (IP3) and release of Ca2+ from the endoplasmic reticulum. To examine the role of Ca2+, we used the Ca2+chelator, BAPTA/AM, in studies in slices. Preincubation with 20 µM BAPTA/AM did not change the basal phosphorylation of DARPP-32, but the effect of DHPG was abolished (Fig. 1). Moreover, treatment of slices with the Ca2+ ionophore, ionomycin (2 µM), resulted in increased phosphorylation of both Ser-137 and Thr-75 of DARPP-32 (Fig. 1). Based on previous studies of the regulation of CK1epsilon (13, 17, 18), we hypothesized that increased intracellular Ca2+ might activate a Ca2+-dependent protein phosphatase to dephosphorylate inhibitory autophosphorylation sites on CK1. The Ca2+-dependent phosphatase, calcineurin (PP2B), is expressed at high levels in striatum (25). Treatment of slices with cyclosporin A (5 µM), a specific calcineurin inhibitor, for 1 h attenuated the effect of DHPG on phosphorylation of Ser-137 and Thr-75 of DARPP-32 (Fig. 1).

The Effect of DHPG on CKIepsilon Activity Is Blocked by U73122, BAPTA, and Cyclosporin A-- To further characterize the effect of DHPG on CK1epsilon activity, we used a transfection system. An expression plasmid containing HA-tagged CK1epsilon was transiently transfected into N2a cells, and cells were treated with DHPG for 2 min. CK1epsilon was immunoprecipitated using anti-HA antibody, and CK1epsilon activity was assayed using DARPP-32 as substrate (Fig. 2). An initial screen for different subtypes of group I mGluRs indicated that mGluR1 is expressed in N2a cells. For example, treatment of cells with DHPG resulted in an increase in CK1epsilon activity; this effect was blocked by the group I mGluR antagonist L-AP3 (Fig. 2). Preincubation of cells with U73122 (10 µM), BAPTA/AM (20 µM), or cyclosporin A (1 µM) abolished the effect of DHPG on CK1epsilon activity, consistent with a role for Ca2+-dependent activation of calcineurin in the regulation of CK1epsilon .


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 2.   The effect of DHPG on CK1epsilon activity is blocked by BAPTA/AM and cyclosporin A. N2a cells were transiently transfected with HA-tagged CK1epsilon . Cells were preincubated without or with the group I mGluR antagonist L-AP3 (100 µM for 20 min), U73122 (12.5 µM for 20 min), BAPTA/AM (BAPTA, 20 µM for 20 min), or cyclosporin A (Cy A, 1 µM for 20 min) prior to treatment without or with DHPG (100 µM for 2 min). HA-CK1epsilon was immunoprecipitated, and CK1 was assayed using DARPP-32 as a substrate. Samples were analyzed by SDS-PAGE and autoradiography. Top panel, autoradiogram of DARPP-32 phosphorylation; middle panel, immunoblot using HA antibody; bottom panel, cumulative data obtained from five experiments (means ± S.E.). Data for each sample were normalized to the total level of HA-CK1epsilon . Data were then normalized to the value obtained in the absence of any addition (-DHPG, set as 1). Data were normalized to values for untreated cells. *, p < 0.05, Student's t test, compared with untreated cells.

DHPG Regulates Cdk5 Kinase Activity through a PLCbeta /Ca2+/Calcineurin Pathway-- Previously we demonstrated by using specific CK1 inhibitors that group I mGluRs activate Cdk5 kinase activity via a pathway that involves CK1. To further examine whether Cdk5 activation by DHPG is through a PLCbeta /Ca2+/calcineurin pathway, we analyzed Cdk5 kinase activity following its immunoprecipitation from mouse neostriatal slices. Preincubation of mouse neostriatal slices with U73122 (12.5 µM), BAPTA/AM (20 µM) for 30 min, or cyclosporin A (5 µM) for 60 min abolished the effect of DHPG on Cdk5 activity (Fig. 3). Treatment of slices with ionomycin (2 µM) for 2 min also resulted in an increase in Cdk5 kinase activity by 2-fold; the effect of ionomycin was blocked by cyclosporin A (5 µM).


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 3.   The effect of DHPG on Cdk5 activity is blocked by U73122, BAPTA/AM, and cyclosporin A. Mouse neostriatal slices were preincubated with U73122 (12.5 µM for 20 min), BAPTA/AM (BAPTA, 20 µM for 20 min), or cyclosporin A (Cy A, 5 µM for 60 min) and then without or with DHPG (100 µM for 2 min) or ionomycin (Iono., 2 µM for 2 min). Slices were homogenized, and Cdk5 was immunoprecipitated with anti-Cdk5 (C-8) antibody. Cdk5 activity was assayed using histone H-1 as substrate, and samples were analyzed by SDS-PAGE and autoradiography. The top and middle panels show autoradiograms indicating histone H-1 phosphorylation. The bottom panel shows cumulative data (means ± S.E.) from three experiments. Data for each sample were normalized to the total level of cdk5 (determined by immunoblotting, not shown). Data were then normalized to the value obtained in the absence of any addition (-DHPG, set as 1). *, p < 0.05, Student's t test, compared with untreated slices.

DHPG Treatment Induces Transient Dephosphorylation of CKIepsilon -- The ability of cyclosporin A to block the effect of DHPG suggested that the regulation of CK1epsilon by DHPG might involve direct dephosphorylation of CK1epsilon by calcineurin. To examine the phosphorylation state of CK1epsilon in response to DHPG, N2a cells that expressed HA-CK1epsilon were metabolically labeled with 32P and then treated with DHPG for various periods of time. HA-CK1epsilon was immunoprecipitated, separated by SDS-PAGE (Fig. 4a), and then subjected to two-dimensional phosphopeptide mapping (Fig. 4b). There was little apparent change in the total level of phosphorylation of CK1epsilon after incubation of cells with DHPG (Fig. 4a). However, peptide mapping revealed that DHPG treatment resulted in rapid and transient dephosphorylation of a subset of phosphopeptides (Fig. 4b). At time 0 (in the absence of DHPG), wild-type CK1epsilon was found to be strongly phosphorylated at one site (basic peptide labeled "C " in Fig. 4b, top left). In addition, 7-10 negatively charged peptides were phosphorylated (acidic sites, circled in Fig. 4b, top left). Treatment with DHPG for 2 or 4 min resulted in the dephosphorylation of the acidic peptides, whereas there was no dephosphorylation of the control (basic) peptide. Indeed, after calculating the relative radioactivity in the acidic peptides and in the C peptide, phosphorylation of the C peptide actually increased ~2-fold at 2 or 4 min. Ten minutes after DHPG treatment, the phosphorylation level of the acidic peptides, and also of the C peptide, returned close to the same levels observed in the "0 min" time point sample. Preincubation of cells with cyclosporin A (1 µM) for 30 min before the addition of DHPG prevented the transient dephosphorylation of the acidic peptides in CK1epsilon (Fig. 4c, measured at the 4 min time point). Together these results indicate that DHPG stimulates calcineurin and results in transient dephosphorylation of a subset of autophosphorylation sites in CK1epsilon , whereas phosphorylation of a separate site increases transiently.


View larger version (67K):
[in this window]
[in a new window]
  		Fig. 4.   CK1epsilon is transiently dephosphorylated upon DHPG treatment. N2a cells were transiently transfected with HA-CK1epsilon . Cells were incubated with 200 µCi/ml H332PO4 in phosphate-free medium for 2 h. For the last 30 min of labeling, cells were treated without or with cyclosporin A (Cy A, 1 µM) and then without or with DHPG for various times as indicated. a, HA-CK1epsilon was immunoprecipitated, and samples were analyzed by SDS-PAGE and autoradiography (upper panel). The lower panel shows an immunoblot using HA antibody. Radioactivity was determined using a PhosphorImager and ImageQuant software. The values obtained were: - DHPG, 10522; 2 min DHPG, 12204; 4 min DHPG, 10606; 10 min DHPG, 9540. b, gel bands containing 32P-labeled HA-CK1epsilon were subjected to two-dimensional tryptic phosphopeptide mapping. Electrophoresis was in the horizontal direction (positive electrode at left, point of origin marked by arrowhead in top left), and chromatography was in the vertical direction. Radioactivity in the phosphopetides for each peptide map was determined using a PhosphorImager and ImageQuant software. To account for variations in the peptide mapping process, the ratios in the radioactivity of the circled peptides and the C peptide were used to calculate the absolute radioactivity from the values obtained for phosphorylation of HA-CK1epsilon (see above). The values obtained were: - DHPG, 4840 in the circled peptides, 5682 in the C peptide; 2 min DHPG, 366 in the circled peptides, 11900 in the C peptide; 4 min DHPG, 0 in the circled peptides, 10606 in the C peptide; 10 min DHPG, 3339 in the circled peptides, 6201 in the C peptide. c, cells transfected with HA-CK1epsilon were incubated with cyclosporin A (Cy A) and DHPG for 0 or 4 min, as indicated. Cell extracts were analyzed as described in a and b.

C-terminal Autophosphorylation of CKIepsilon Is Involved in Regulation of Its Activity by DHPG-- Eight phosphorylation sites in the C-terminal domain of CK1epsilon were identified as probable in vivo autophosphorylation sites (18). To further examine the details of CK1epsilon activation, we tested a mutant of CK1epsilon , MM2, that lacked the eight sites (S323A/T325A/T334A/T337A/S368A/S405A/T407A/S408A). Myc-MM2-CK1epsilon was transiently transfected into N2a cells, immunoprecipitated, and subjected to phosphopeptide mapping and kinase activity assay. Phosphopeptide mapping revealed that MM2-CK1epsilon was autophosphorylated only at the control (basic) peptide, and treatment with DHPG had no effect on phosphorylation of this site (Fig. 5a and data not shown). Treatment with DHPG had no effect on MM2-CK1epsilon activity assayed using DARPP-32 as substrate, and this was also unaffected by preincubation with cyclosporin A (Fig. 5b). The expression level of Myc-tagged MM2-CK1epsilon in N2a cells was about the same as the HA-tagged wild-type CK1epsilon , but the immunoprecipitated MM2-CK1epsilon was ~2-fold more active than HA-CK1epsilon (Fig. 5b).


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 5.   A CK1epsilon mutant lacking inhibitory autophosphorylation sites is not activated by DHPG. N2a cells were transiently transfected with either wild-type HA-tagged CK1epsilon or Myc-tagged MM2-CK1epsilon , a mutant enzyme in which Ser-323, Thr-325, Thr-334, Thr-337, Ser-368, Ser-405, Thr-407, and Ser-408 are mutated to alanine. a, cells were labeled with 200 µCi/ml H332PO4 in phosphate-free medium for 2 h and treated with DHPG for 2 min. HA- or Myc-tagged CKIepsilon was immunoprecipitated, analyzed by SDS-PAGE and subjected to phosphopeptide mapping as described in the legend to Fig. 4. b, cells were pretreated without or with cyclosporin A (Cy A, 1 µM for 30 min) prior to incubation without or with DHPG (100 µM for 2 min). HA-CK1epsilon or MM2-CK1epsilon was immunoprecipitated, and CK1epsilon activity was assayed using DARPP-32 as a substrate. Samples were analyzed by SDS-PAGE and autoradiography. Top panel, autoradiogram of DARPP-32 phosphorylation; middle panel, immunoblot showing expression of HA- or Myc-tagged CK1epsilon using an anti-CK1 antibody that recognized both wild-type and MM2-CK1epsilon ; bottom panel, cumulative kinase activity data obtained from five experiments (mean ± S.E.). Data for each sample were normalized to the total level of CK1epsilon . Data were then normalized to the value obtained in the absence of any addition (-DHPG, set as 1). *, p < 0.05, Student's t test compared with untreated cells; #, p < 0.001, Student's t test compared with untreated cells that were transfected with wild-type HA-CKIepsilon .

Previous studies carried out in vitro had suggested that inhibitory autophosphorylation site(s) within the catalytic domain might also contribute to autoinhibition of CK1epsilon (17). The phosphopeptide maps revealed that the control (basic) phosphopeptide was present in both wild-type and MM2-CKIepsilon , and that phosphorylation of this site increased transiently in wild-type CK1epsilon (but, notably, not in MM2-CK1epsilon ) following treatment with DHPG (Figs. 4 and 5). The identity of the control site phosphorylated under basal conditions is not known. To examine whether phosphorylation of this site has any influence on CKIepsilon activity, tagged CK1epsilon was immunoprecipitated from N2a cell lysates and incubated with nonspecific lambda protein phosphatase. The incubation with lambda phosphatase substantially reduced phosphorylation of either wild-type or MM2-CK1epsilon , as revealed by studies in which cells were prelabeled with 32P (and treated with DHPG) (Fig. 6a, upper panel). Other samples were prepared in parallel with unlabeled N2a cells and treated with lambda phosphatase, and CK1 activity was assayed using DARPP-32 as substrate. Phosphatase treatment did not apparently affect the activity of wild-type or MM2-CKIepsilon (all cells were preincubated with DHPG) (Fig. 6a, lower panel, and Fig. 6b), suggesting that phosphorylation of the control site in intact cells did not regulate CK1epsilon .


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 6.   Constitutive phosphorylation of CK1epsilon does not regulate enzyme activity. N2a cells were transfected with HA-CK1epsilon or MM2-CKIepsilon . a, cells were labeled with H332PO4 in phosphate-free medium (200 µCi/ml for 2 h) and then treated with DHPG for 2 min. HA-CK1epsilon or MM2-CKIepsilon were immunoprecipitated and incubated without or with lambda protein phosphatase for 15 min. 32P-labeled samples were analyzed by SDS-PAGE and autoradiography (upper panel). Other samples prepared in parallel were analyzed for CK1 activity using DARPP-32 as substrate (lower panel). b, cumulative kinase activity data obtained from three experiments (means ± S.E.). Data for each sample were normalized to the total level of CK1epsilon . Data were then normalized to the value obtained in the absence of any addition (-DHPG set as 1; not shown).

Comparison of our phosphopeptide maps with those obtained in a previous study of wild-type CK1epsilon and a kinase-dead mutant suggest that the control site might not be autophosphorylated by an intramolecular mechanism (cf. peptide f in Fig. 1B in Gietzen et al. (18)) and could possibly be phosphorylated by another protein kinase in intact cells. In the present study, we found that as the activity of CK1epsilon was stimulated ~2-fold by dephosphorylation of a subset of inhibitory sites, phosphorylation of the control site was increased ~2-fold (see Fig. 4, a and b). This observation supports the idea that the phosphorylation of the control site is linked directly to the activity of CK1epsilon and probably occurs, at least in part, via autophosphorylation.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In the present study we have examined the signal transduction pathway that links stimulation of group I mGluRs to CK1epsilon activation. The results obtained are consistent with the mechanism illustrated in Fig. 7. Activation of mGluR1 receptors stimulates G proteins that are coupled to PLCbeta ; Ca2+ released from IP3-sensitive stores actives the Ca2+/calmodulin-dependent phosphatase, calcineurin; and calcineurin dephosphorylates the inhibitory autophosphorylation sites on CKIepsilon . Dephosphorylation of CK1epsilon results in an increase in kinase activity. However, this increase is transient because of the subsequent autophosphorylation and autoinhibition of the kinase.


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 7.   Model for regulation of CK1 activity by activation of group I mGluRs. DHPG activates group I mGluRs that are coupled to PLCbeta via Gq. Activation of PLCbeta generates IP3, and IP3 binds to IP3 receptors on the endoplasmic reticulum and releases Ca2+ into the cytosol. Elevated intracellular Ca2+actives the Ca2+-dependent phosphatase calcineurin, which in turn dephosphorylates the regulatory autophosphorylation sites on CKIepsilon . CKIepsilon is transiently activated, but gradual autophosphorylation restores the inhibited level of kinase activity. A site that is basally phosphorylated is likely to be present within the kinase domain but does not appear to regulate enzyme activity.

Our previous studies had shown that in neostriatal slices, DHPG, an agonist for group I mGluRs, increased CK1 activity, leading to enhanced phosphorylation of Ser-137 of DARPP-32. In the present study, we found that the phosphorylation of Ser-137 of DARPP-32 in neostriatal neurons was sensitive to U73122, BAPTA, and cyclosporin A. The phosphorylation of Thr-75 was also sensitive to these inhibitors, supporting our previous results indicating that activation of CK1 leads to activation of Cdk5 (19). The present results, from studies carried out largely using transfected cell lines, support the conclusion that CK1epsilon is the likely target for regulation by type I mGluRs in neostriatal neurons. However, it is possible that other CK1 isoforms may be activated through a pathway similar to that shown in Fig. 7. The C-terminal 125 amino acids of CK1delta is ~50% identical to the corresponding domain of CK1epsilon . In addition, several in vitro studies have found that the activity of CK1delta , like CK1epsilon , is regulated by autophosphorylation (16, 26). In vitro studies have also indicated that all three CK1gamma isoforms can be autophosphorylated (16), raising the possibility that these isoforms are regulated as well. CK1alpha , -delta , and -epsilon isoforms have all been found to be expressed in brain and are likely to be distributed widely in neurons (27-29). In addition, our preliminary results indicate that CK1alpha , -delta , and -epsilon isoforms are expressed in neostriatum (data not shown). Thus it is possible that activation of calcineurin could lead to transient activation of several CK1 isoforms in neostriatal slices (see also further discussion below).

The precise molecular mechanism by which autophosphorylation of CK1 isoforms regulates enzyme activity is not clear. Autophosphorylation of multiple C-terminal sites in CK1delta and CK1epsilon appear to be required, although the precise relationship between individual sites and enzyme activity remains to be clarified (16-18). Autophosphorylation is associated with inhibition of enzyme activity toward protein substrates but does not affect phosphorylation of some short synthetic peptides. This latter observation suggests that autophosphorylation serves to influence protein substrate binding negatively by a process that does not block access to the active site of the kinase. Ser-137, the site phosphorylated in DARPP-32 by CK1, is situated at the C-terminal end of a highly acidic region of the protein (23 of 30 residues are either glutamate or aspartate) (30). Possibly, the phosphorylated C-terminal domain of CK1epsilon (or other isoforms) could act to block binding of longer polypeptide substrates containing acidic domains but not shorter synthetic peptides. Dephosphorylation of the C-terminal domain would then lead to a loss of this inhibitory constraint. Alternatively, an unphosphorylated C-terminal domain (which in CK1epsilon contains a significant excess of basic amino acids) could serve a positive role in binding to polypeptide substrates that contain acidic domains.

The present study establishes that autophosphorylation of CK1epsilon at least is a regulated physiological event in intact cells. Although we did not investigate in detail the identity of the site(s) of autophosphorylation that are regulated by calcineurin, the results provide some further insight into the molecular events involved in regulation of CK1epsilon activity in intact cells. Previous studies of CK1epsilon have indicated that at least eight sites are autophosphorylated in vitro. However, in intact cells autophosphorylation of many of these sites is apparent only in the presence of okadaic acid or calyculin A, inhibitors of PP1 and PP2A (18, 26). Moreover, autophosphorylation of these sites in the presence of PP1/PP2A inhibitors is associated with a decrease in electrophoretic mobility, detected using SDS-PAGE. In the present study, a significant level of autophosphorylation of CK1epsilon was observed in intact cells under basal conditions. Moreover, treatment with DHPG or cyclosporin A had no effect on the electrophoretic mobility of the protein, despite the dephosphorylation of a subset of the sites phosphorylated. A reasonable explanation for these results is that there are a least two subsets of autophosphorylation sites. One set is subject to dephosphorylation by calcineurin, is not associated with any alteration of electrophoretic mobility, and is phosphorylated under basal conditions in intact cells as long as calcineurin is inactive. The second set is subject to dephosphorylation by PP1 or PP2A, is associated with a decrease in electrophoretic mobility, and is maintained in a dephosphorylated state in intact cells by active PP1 or PP2A. Additional mutagenesis will be required to identify the site(s) in CK1epsilon that are specifically dephosphorylated by either calcineurin or PP1/PP2A in intact cells.

The results from our present study indicate that one or more of the sites phosphorylated under basal conditions, and dephosphorylated by activated calcineurin, is associated with regulation of CK1epsilon activity. It also seems likely that autophosphorylation of one or more of the sites dephosphorylated in intact cells by PP1/PP2A may be associated with regulation of CK1epsilon activity. Although the sites that are sensitive to PP1/PP2A are maintained in a dephosphorylated state in cells in culture (and apparently in neostriatal neurons under basal conditions), it is possible that physiological inhibition of PP1 or PP2A would result in additional inhibition of CK1epsilon . For example, in neostriatal neurons, stimulation of phosphorylation of DARPP-32 by D1 dopamine receptors would lead to inhibition of PP1 and could influence CK1epsilon activity. Further studies will be required to determine whether autophosphorylation of these different sets of sites results in independent modes of regulation of CK1epsilon or whether there is some sort of interdependence between autophosphorylation of the different sites and regulation of CK1. Autophosphorylation of different sites could have additive or synergistic effects, could cause them to occlude one another, or perhaps could even modulate the ability of CK1 to interact with distinct substrates. Interestingly, three of the eight sites in CK1epsilon (Thr-325, Ser-368, and Ser-405) appear to be conserved in CK1delta . It is possible that these conserved sites might also confer regulation of CK1delta by calcineurin in intact cells. Alternatively, different autophosphorylation sites may be used to confer differential physiological regulation of CK1 isoforms by protein phosphatases.

The present studies were motivated by our original observations indicating that CK1 could phosphorylate Ser-137 of DARPP-32 (31, 32). Phosphorylation of Ser-137 impairs the ability of Thr-34 of DARPP-32 to be dephosphorylated by calcineurin, thereby modulating the DARPP-32/PP1 cascade. Our more recent studies support the conclusion that activation of CK1 by group I mGluRs results in phosphorylation of Ser-137 of DARPP-32 in neostriatal neurons and that this leads to regulation of voltage-dependent Ca2+ channels (19). A variety of other studies have provided strong support for a role of CK1 isoforms, particularly CK1delta and CK1epsilon , in diverse cellular processes such as regulation of Wnt signaling and of the circadian clock (7-11, 13-15). CK1delta and CK1epsilon have also been implicated in the pathophysiology of Alzheimer's disease (28, 33, 34). Regulation of CK1epsilon (and possibly CK1delta ) by autophosphorylation and transient dephosphorylation by calcineurin may play an important role in the regulation of these other processes that involve the enzyme. Activation of calcineurin may result from stimulation of mGluRs or via many alternative pathways that increase the concentration of intracellular Ca2+ in mammalian cells. Regulation of CK1epsilon also adds to the diversity of signal transduction pathways utilized by mGluRs and may be responsible for various actions of this increasingly important family of G protein-coupled receptors (35, 36). Finally, the results from these studies indicate that CK1epsilon represents an additional example of a group of protein kinases including Cdks, Src family members, and Raf-1 (37-39) that are inhibited by phosphorylation and that require dephosphorylation to allow signaling to occur.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, 1230 York Ave., New York, NY 10021. Tel.: 212-327-8871; Fax: 212-327-7888; E-mail: nairn@mail.rockefeller.edu.

Published, JBC Papers in Press, September 9, 2002, DOI 10.1074/jbc.M204499200

    ABBREVIATIONS

The abbreviations used are: CK1, casein kinase 1; HA, hemagglutinin; mGluR, metabotropic glutamate receptor; PP, protein phosphatase; DHPG, (S)-3,5-dihydroxypenylglycine; DARPP-32, dopamine and cAMP-regulated phosphoprotein, 32 kDa; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; TPCK, L-1-tosylamido-2-phenylethyl chloromethyl ketone; PLCbeta , phospholipase Cbeta ; IP3, inositol 1,4,5-triphosphate; Cdk, cyclin-dependent kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Gross, S. D., and Anderson, R. A. (1998) Cell. Signal. 10, 699-711[CrossRef][Medline] [Order article via Infotrieve]
2. Vielhaber, E., and Virshup, D. M. (2001) IUBMB Life 51, 73-78[CrossRef][Medline] [Order article via Infotrieve]
3. Tobin, A. B., Totty, N. F., Sterlin, A. E., and Nahorski, S. R. (1997) J. Biol. Chem. 272, 20844-20849[Abstract/Free Full Text]
4. Budd, D. C., McDonald, J. E., and Tobin, A. B. (2000) J. Biol. Chem. 275, 19667-19675[Abstract/Free Full Text]
5. Knippschild, U., Milne, D. M., Campbell, L. E., DeMaggio, A. J., Christenson, E., Hoekstra, M. F., and Meek, D. W. (1997) Oncogene 15, 1727-1736[CrossRef][Medline] [Order article via Infotrieve]
6. Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., and Appella, E. (2000) J. Biol. Chem. 275, 9278-9283[Abstract/Free Full Text]
7. Sakanaka, C., Leong, P., Xu, L., Harrison, S. D., and Williams, L. T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12548-12552[Abstract/Free Full Text]
8. Peters, J. M., McKay, R. M., McKay, J. P., and Graff, J. M. (1999) Nature 401, 345-350[CrossRef][Medline] [Order article via Infotrieve]
9. McKay, R. M., Peters, J. M., and Graff, J. M. (2001) Dev. Biol. 235, 388-396[CrossRef][Medline] [Order article via Infotrieve]
10. Gao, Z. H., Seeling, J. M., Hill, V., Yochum, A., and Virshup, D. M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 1182-1187[Abstract/Free Full Text]
11. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X., and He, X. (2002) Cell 108, 837-847[CrossRef][Medline] [Order article via Infotrieve]
12. Eide, E. J., and Virshup, D. M. (2001) Chronobiol. Int. 18, 389-398[CrossRef][Medline] [Order article via Infotrieve]
13. Lowrey, P. L., Shimomura, K., Antoch, M. P., Yamazaki, S., Zemenides, P. D., Ralph, M. R., Menaker, M., and Takahashi, J. S. (2000) Science 288, 483-492[Abstract/Free Full Text]
14. Toh, K. L., Jones, C. R., He, Y., Eide, E. J., Hinz, W. A., Virshup, D. M., Ptacek, L. J., and Fu, Y. H. (2001) Science 291, 1040-1043[Abstract/Free Full Text]
15. Lee, C., Etchegaray, J. P., Cagampang, F. R., Loudon, A. S., and Reppert, S. M. (2001) Cell 107, 855-867[CrossRef][Medline] [Order article via Infotrieve]
16. Graves, P. R., and Roach, P. J. (1995) J. Biol. Chem. 270, 21689-21694[Abstract/Free Full Text]
17. Cegielska, A., Gietzen, K. F., Rivers, A., and Virshup, D. M. (1998) J. Biol. Chem. 273, 1357-1364[Abstract/Free Full Text]
18. Gietzen, K. F., and Virshup, D. M. (1999) J. Biol. Chem. 274, 32063-32070[Abstract/Free Full Text]
19. Liu, F., Ma, X. H., Ule, J., Bibb, J. A., Nishi, A., DeMaggio, A. J., Yan, Z., Nairn, A. C., and Greengard, P. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 11062-11068[Abstract/Free Full Text]
20. Bibb, J. A., Snyder, G. L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A. A., Tsai, L. H., Kwon, Y. T., Girault, J. A., Czernik, A. J., Huganir, R. L., Hemmings, H. C., Jr., Nairn, A. C., and Greengard, P. (1999) Nature 402, 669-671[CrossRef][Medline] [Order article via Infotrieve]
21. Nishi, A., Snyder, G. L., and Greengard, P. (1997) J Neurosci 17, 8147-8155[Abstract/Free Full Text]
22. Conn, P. J., and Pin, J. P. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 205-237[CrossRef][Medline] [Order article via Infotrieve]
23. Paolillo, M., Montecucco, A., Zanassi, P., and Schinelli, S. (1998) Eur. J. Neurosci. 10, 1937-1945[CrossRef][Medline] [Order article via Infotrieve]
24. Cartmell, J., Goepfert, F., Knoflach, F., Pink, J. R., Bleuel, Z., Richards, J. G., Schaffhauser, H., Kemp, J. A., Wichmann, J., and Mutel, V. (1998) Brain Res. 791, 191-199[CrossRef][Medline] [Order article via Infotrieve]
25. Goto, S., Matsukado, Y., Mihara, Y., Inoue, N., and Miyamoto, E. (1986) Brain Res. 397, 161-172[CrossRef][Medline] [Order article via Infotrieve]
26. Rivers, A., Gietzen, K. F., Vielhaber, E., and Virshup, D. M. (1998) J. Biol. Chem. 273, 15980-15984[Abstract/Free Full Text]
27. Graves, P. R., Haas, D. W., Hagedorn, C. H., DePaoli-Roach, A. A., and Roach, P. J. (1993) J. Biol. Chem. 268, 6394-6401[Abstract/Free Full Text]
28. Ghoshal, N., Smiley, J. F., DeMaggio, A. J., Hoekstra, M. F., Cochran, E. J., Binder, L. I., and Kuret, J. (1999) Am. J. Pathol. 155, 1163-1172[Abstract/Free Full Text]
29. Takano, A., Shimizu, K., Kani, S., Buijs, R. M., Okada, M., and Nagai, K. (2000) FEBS Lett. 477, 106-112[CrossRef][Medline] [Order article via Infotrieve]
30. Hemmings, H. C., Jr., Nairn, A. C., Elliott, J. I., and Greengard, P. (1990) J. Biol. Chem. 265, 20369-20376[Abstract/Free Full Text]
31. Desdouits, F., Cohen, D., Nairn, A. C., Greengard, P., and Girault, J. A. (1995) J. Biol. Chem. 270, 8772-8778[Abstract/Free Full Text]
32. Desdouits, F., Siciliano, J. C., Greengard, P., and Girault, J. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2682-2685[Abstract/Free Full Text]
33. Kuret, J., Johnson, G. S., Cha, D., Christenson, E. R., DeMaggio, A. J., and Hoekstra, M. F. (1997) J. Neurochem. 69, 2506-2515[Medline] [Order article via Infotrieve]
34. Schwab, C., DeMaggio, A. J., Ghoshal, N., Binder, L. I., Kuret, J., and McGeer, P. L. (2000) Neurobiol. Aging 21, 503-510[CrossRef][Medline] [Order article via Infotrieve]
35. Sallese, M., Iacovelli, L., Cumashi, A., Capobianco, L., Cuomo, L., and De Blasi, A. (2000) Biochim Biophys Acta 1498 (2-3), 112-121[Medline] [Order article via Infotrieve]
36. Hermans, E., and Challiss, R. A. (2001) Biochem. J. 359, 465-484[CrossRef][Medline] [Order article via Infotrieve]
37. Williams, J. C., Wierenga, R. K., and Saraste, M. (1998) Trends Biochem. Sci. 23, 179-184[CrossRef][Medline] [Order article via Infotrieve]
38. Obaya, A. J., and Sedivy, J. M. (2002) Cell. Mol. Life Sci. 59, 126-142[CrossRef][Medline] [Order article via Infotrieve]
39. Dhillon, A. S., Meikle, S., Yazici, Z., Eulitz, M., and Kolch, W. (2002) EMBO J. 21, 64-71[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
A. G. Grozav, K. Chikamori, T. Kozuki, D. R. Grabowski, R. M. Bukowski, B. Willard, M. Kinter, A. H. Andersen, R. Ganapathi, and M. K. Ganapathi
Casein kinase I {delta}/{varepsilon} phosphorylates topoisomerase II{alpha} at serine-1106 and modulates DNA cleavage activity
Nucleic Acids Res., November 29, 2008; (2008) gkn934v1.